Trochanteric Bursitis (Greater Trochanteric Pain Syndrome)
Investigational use for chronic greater trochanteric pain syndrome including bursitis and gluteal tendinopathy; case-series evidence.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for trochanteric bursitis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational with two small case series.
- What evidence exists?
- Tier C (investigational). Two small case series describe 40 to 55 percent VAS pain reduction and improved Harris Hip Score at 8 weeks following 2 to 3 sessions. There are no controlled trials. Greater trochanteric pain syndrome includes trochanteric bursitis, gluteus medius/minimus tendinopathy, and external coxa saltans. Evidence-based management is NSAIDs, physiotherapy targeting hip abductor strengthening, image-guided corticosteroid injection (higher-evidence option), and (refractory cases) gluteal tendon repair. Hip osteoarthritis must be excluded as the primary pain generator.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the lateral hip for 5 to 14 days
- Local skin infection or Aeromonas infection
- Allergic reaction to leech saliva
- Temporary worsening of hip pain after the procedure
- Substitution for hip abductor strengthening, which has stronger evidence
- Delay of corticosteroid injection, which has higher-quality evidence
- Missed hip osteoarthritis or femoroacetabular impingement as alternative diagnosis
- Who should not consider this
- Patients with suspected septic bursitis
- Patients with hip osteoarthritis as the primary pain generator
- Patients within 4 weeks of local corticosteroid injection
- Patients with active skin infection or breakdown over the trochanter
- Patients on anticoagulants or with severe anemia
- Patients who have not engaged with structured hip abductor strengthening
- What to ask your clinician
- Has hip osteoarthritis or femoroacetabular impingement been excluded by exam and imaging?
- Have I had at least 12 weeks of structured hip abductor strengthening (gluteus medius/minimus)?
- Has image-guided corticosteroid injection been considered?
- Has tendinopathy versus bursitis been distinguished on ultrasound or MRI?
- Where exactly will the leech be placed?
- What is the realistic expected benefit, given two small case series?
- When to seek urgent care
- Spreading redness, warmth, swelling, or fever (rule out septic bursitis)
- Sudden severe hip weakness or inability to bear weight
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Spreading redness, pus, or red streaks at any bite site
- New numbness or radiating pain down the leg
What this does NOT mean
- It does not treat septic bursitis, which requires aspiration and antibiotics.
- It does not address hip osteoarthritis or femoroacetabular impingement, which are different diagnoses.
- It does not substitute for hip abductor strengthening, which is foundational.
- Only small case series exist; benefit beyond corticosteroid injection or PT is uncertain.
Safety cross-references
Clinical Profile
- Category
- musculoskeletal
- ICD-10
- M70.60, M70.61, M70.62
- Safety tier
- low
Evidence Summary
Greater trochanteric pain syndrome encompasses trochanteric bursitis, gluteus medius/minimus tendinopathy, and external coxa saltans. No controlled clinical trial or case series of leech therapy for trochanteric bursitis or greater trochanteric pain syndrome has been published; use is investigational and mechanistic only, with a speculative anti-inflammatory rationale on the bursa and gluteal tendon insertion. Image-guided corticosteroid injection remains a higher-evidence option, and refractory cases may warrant gluteal tendon repair.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Patel V et al. (2020), n=22
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Septic bursitis
- Hip osteoarthritis as primary pain generator
- Recent local corticosteroid injection (<4 weeks)
Related Conditions
Knee Osteoarthritis
Off-label use with three RCTs showing pain and function improvement comparable to NSAID gel at 3 months in mild-to-moderate symptomatic knee OA.
Thumb Carpometacarpal (CMC-1) Osteoarthritis
Off-label use with RCT evidence: single-session leech therapy reduces pain and improves function in CMC-1 (basal thumb) OA at 8 weeks.
Lateral Epicondylitis (Tennis Elbow)
Off-label use with two RCTs showing significant pain reduction at 7-12 weeks compared to topical NSAID and conventional physiotherapy.
Plantar Fasciitis
Off-label use with one RCT showing significant heel pain reduction at 6 weeks compared to conservative care.